Telix Pharmaceuticals Limited
TLPPF
$16.05
-$0.1419-0.88%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.60M | 6.79M | 7.70M | 11.82M | 6.36M |
| Total Depreciation and Amortization | 1.41M | 1.45M | 1.60M | 836.50K | 1.16M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.22M | 14.62M | 12.85M | -9.06M | 6.86M |
| Change in Net Operating Assets | -20.94M | -21.53M | -- | -- | -10.92M |
| Cash from Operations | 1.29M | 1.32M | 22.15M | 3.60M | 3.46M |
| Capital Expenditure | -7.85M | -8.07M | -1.52M | -1.57M | -2.17M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -2.51M | -2.58M | -15.28M | -- | -40.10K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.75M | -19.28M | -7.53M | -4.30M | -5.15M |
| Cash from Investing | -29.11M | -29.93M | -24.34M | -5.86M | -7.37M |
| Total Debt Issued | 326.62M | 326.62M | 1.50M | 1.20M | 1.64M |
| Total Debt Repaid | -974.50K | -974.50K | -1.18M | -- | -755.50K |
| Issuance of Common Stock | 182.50K | 182.50K | 471.00K | 163.00K | 1.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.44M | -7.44M | 2.83M | -2.83M | -- |
| Cash from Financing | 207.47M | 213.33M | 2.38M | -963.40K | 1.79M |
| Foreign Exchange rate Adjustments | 13.07M | 13.44M | -2.75M | 2.88M | -651.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 192.72M | 198.17M | -2.55M | -347.90K | -2.77M |
